FRANKFURT (Reuters) – Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and last phase of testing on humans.
Roche said in a statement that the experimental antibiotic zosurabalpin, jointly developed with Harvard University, would be tested against acinetobacter baumannii, relying on a new mode of action that bacteria have not developed resistance against.
Drug-resistant acinetobacter are present across the world and disproportionately impact patients who are in hospital, causing serious infections like pneumonia and sepsis, the company added.
(Reporting by Ludwig Burger, editing by Rachel More)
Comments